The end of Alzheimer’s?
Preview text: A prevention strategy is in clinical trials
Use this example
- Subject
- The end of Alzheimer’s?
- Preview text
- A prevention strategy is in clinical trials
- From
- peter@
peterattiamd.com - Brand
- Peter Attia, M.D.
- ESP
- Klaviyo
- Sent
- Wed Sep 30, 2026, 7:03 AM ET
- Sent to
- peterattiamd.com
- Size
- 47 KB
- Images
- 6
- Links
- 9, 5 of them buttons
- Subject length
- 23 characters
Against Peter Attia, M.D.'s usual
Sent in its busiest hour, 7 AM, which holds 100% of its emails. The subject is 23 characters; its average is 66.
Email headers
What the brand's servers put on this email. Our receiving servers, the address we subscribed with and unsubscribe links are left out.
- From
- Peter Attia, M.D. <[email protected]>
- Subject
- The end of Alzheimer’s?
- Date
- Wed, 30 Sep 2026 11:03:38 +0000
- Message-ID domain
- klaviyomail.com
- Return-Path domain
- k3.send.peterattiamd.com
- DKIM signature
- d=shared.klaviyomail.com s=def1; d=send.peterattiamd.com s=mtd1
- List-Unsubscribe
- Present, one-click
Servers it passed through, newest first
- from (unnamed) by kmta-mta-green-….servers.clovesoftware.com with SMTP
Other sending headers (names only): X-Mailer-Info-Extra2, X-Mailer-Info, X-Mailer-Info-Extra, X-Kmail-Account, X-Kmail-Message, X-Kmail-Ops, X-Report-Abuse
Sent just before and after
| Oct 11, 2026 7:02 AM | How much do symptomatic treatments for Alzheimer’s disease help? | |
| Oct 5, 2026 7:02 AM | The biology of pregnancy: physiologic adaptation, gestational diabetes, preeclampsia, childbirth, and long-term maternal health | |
| Oct 4, 2026 7:00 AM | Myostatin inhibitors and the paradox of larger but weaker muscles | |
| Sep 30, 2026 7:03 AM | The end of Alzheimer’s? (this email) | |
| Sep 28, 2026 7:01 AM | Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | |
| Sep 27, 2026 7:02 AM | Prioritizing health interventions | |
| Sep 21, 2026 7:01 AM | Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone |
More from Peter Attia, M.D.
All Peter Attia, M.D. emailsNov 9, 2026 7:02 AM
Nov 8, 2026 7:01 AM
Nov 2, 2026 7:02 AM
Who is actually at risk for CTE?
Nov 1, 2026 7:00 AM
A longevity playbook for building strength and muscle mass
Oct 29, 2026 7:00 AM
Oct 26, 2026 7:01 AM
Personalized medicine comes to cancer immunotherapy
Oct 25, 2026 7:03 AM
Oct 19, 2026 7:01 AM
